Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01LCS
|
||||
| Former ID |
DNC002789
|
||||
| Drug Name |
CRA_10655
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [551374] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H21N4O2+
|
||||
| Canonical SMILES |
C1CCC(C1)OC2=CC=CC(=C2[O-])C3[NH+]=C4C=CC(=CC4=N3)C(=[N<br />H2+])N
|
||||
| InChI |
1S/C19H20N4O2/c20-18(21)11-8-9-14-15(10-11)23-19(22-14)13-6-3-7-16(17(13)24)25-12-4-1-2-5-12/h3,6-10,12,19,24H,1-2,4-5H2,(H3,20,21)/p+1
|
||||
| InChIKey |
KNRKSVBVURVZJI-UHFFFAOYSA-O
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Inhibitor | [551374] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.